Cellectar Biosciences, Inc. SEC filings CLRB
Cellectar Biosciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 10-K, was filed on Mar 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 28, 2026 | — |
| DEF 14A | Proxy statement | May 28, 2026 | Jul 7, 2026 |
| PRE 14A | Preliminary proxy statement | May 18, 2026 | May 18, 2026 |
| DEFA14A | Additional proxy material | Jun 11, 2025 | — |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 13, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Apr 18, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 14, 2024 |
| DEF 14A | Proxy statement | Oct 2, 2023 | Oct 25, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 22, 2023 | Oct 25, 2023 |
| DEFA14A | Additional proxy material | Jun 20, 2023 | — |
| DEFA14A | Additional proxy material | Jun 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| DEFA14A | Additional proxy material | Jun 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2022 | Apr 19, 2022 |
| DEF 14A | Proxy statement | May 13, 2021 | Jun 23, 2021 |
| PRE 14A | Preliminary proxy statement | May 3, 2021 | Jun 23, 2021 |
| DEF 14A | Proxy statement | Jan 19, 2021 | Feb 25, 2021 |
| PRE 14A | Preliminary proxy statement | Jan 8, 2021 | Jan 8, 2021 |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 24, 2020 |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 13, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2019 | Apr 17, 2019 |
| DEF 14A | Proxy statement | Jun 11, 2018 | Jul 12, 2018 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2018 | Jun 1, 2018 |
| DEF 14A | Proxy statement | Apr 23, 2018 | May 31, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | Apr 13, 2018 |
| DEF 14A | Proxy statement | Aug 11, 2017 | Sep 12, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 26, 2017 | Jul 26, 2017 |
| DEF 14A | Proxy statement | Apr 25, 2017 | May 31, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2017 | Apr 14, 2017 |
| DEF 14A | Proxy statement | Jun 1, 2016 | Jun 29, 2016 |
| PRE 14A | Preliminary proxy statement | May 13, 2016 | May 13, 2016 |
| DEF 14A | Proxy statement | Jan 7, 2016 | Feb 8, 2016 |
| PRE 14A | Preliminary proxy statement | Dec 28, 2015 | Dec 28, 2015 |
| DEF 14A | Proxy statement | Oct 28, 2015 | Nov 30, 2015 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2015 | Oct 16, 2015 |
| DEFA14A | Additional proxy material | May 27, 2015 | — |
| DEFA14A | Additional proxy material | May 26, 2015 | — |
| DEF 14A | Proxy statement | Apr 22, 2015 | May 28, 2015 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2015 | Apr 10, 2015 |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC. (until Feb 11, 2014); COMMON HORIZONS INC (until Jun 2, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.